Pragmatic approach needed to Ozempic compounding concerns

TGA should crack down on “rogue pharmacists” rather than rolling out a ban on compounding Ozempic (semaglutide), an obesity expert claims  Pragmatism is needed when it comes to regulating the compounding of Ozempic, Professor Gary Wittert from the University of Adelaide says.   The Therapeutic Goods Administration (TGA) is currently conducting a consultation to remove

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Helping parents to help their children: tailoring counselling for pain & fever
Next State launches free flu vax program